Wednesday, October 19, 2022

FDA panel recommends pulling Makena, citing ineffectiveness of controversial preterm birth drug

The FDA advisory panel, made up of gynecologists, obstetricians and other fetal medicine experts, voted 14-1 to withdraw Makena from the market.

      

Stay Informed: Read More Here .

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.